$113 Million

Sagimet Biosciences Inc.

Follow-on Offering

Bookrunner, January 2024

Sagimet Biosciences Inc.

Sagimet Biosciences Inc. (“Sagimet” or the “Company”) is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Sagimet’s lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of NASH, for which there are no treatments currently approved in the United States or Europe.